Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
| ▸ | GALR1 | P47211 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964549 | 0.84 | PDE7B (0.34) | SLC6A3SLC6A2SLC6A4GALR1LMNA | |
| SCHEMBL5963588 | 0.84 | LMNA (0.33) | GALR1ALDH1A1LMNA | |
| SCHEMBL5963556 | 0.82 | KMT2A (0.34) | SLC6A3SLC6A2SLC6A4MAPTLMNA | |
| SCHEMBL5963482 | 0.80 | SLC6A2 (0.34) | SLC6A3SLC6A2SLC6A4KDM4EALDH1A1 | |
| SCHEMBL5963456 | 0.80 | SLC6A2 (0.36) | SLC6A3SLC6A2SLC6A4PDE7B | |
| SCHEMBL5963604 | 0.77 | POLB (0.35) | GALR1KDM4EALDH1A1HPGDPDE7B | |
| SCHEMBL5963362 | 0.76 | GALR1 (0.34) | GALR1ALDH1A1GAAPDE7B | |
| SCHEMBL5004773 | 0.75 | ALDH1A1 (0.36) | SLC6A3SLC6A4ALDH1A1 | |
| SCHEMBL5963816 | 0.75 | OPRM1 (0.35) | ALDH1A1LMNA | |
| SCHEMBL5964210 | 0.75 | AKR1B1 (0.34) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125840-B2 | Substituted dipeptides as growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1326851-B1 | SUBSTITUTED DIPEPTIDES AS GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040058971-A1 | Substituted dipeptides as growth hormone secretagogues | ELI LILLY AND COMPANY | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058971-A1 | Substituted dipeptides as growth hormone secretagogues | GHSR, GHRHR, SSTR4 | SLC6A3 981/4885SLC6A2 1380/4885SLC6A4 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.